Being on the receiving end of a patent infringement lawsuit, especially from a company like Beigene, could introduce significant legal costs and uncertainties for Sandoz and by extension Novartis. This might concern investors, potentially leading to a negative impact on Novartis's stock in the short term. The relevance and importance are not at the maximum due to the broad portfolio and financial strength of Novartis, which might mitigate the impact.

The involvement in a patent infringement lawsuit could bring about negative sentiment towards Sandoz's stock, as investors may be wary of the potential financial implications and the uncertainty of legal outcomes. The impact is considered significant due to the direct legal challenge, but the overall effect might be moderated by the broader context of Sandoz's operations and financial health.

Initiating patent infringement lawsuits is a significant move that often indicates a company's commitment to protecting its intellectual property. For Beigene, this could mean safeguarding key revenue streams, which might be viewed positively by investors. However, the outcome of legal actions is uncertain, hence the confidence score is not at the maximum.